sb 216763 has been researched along with Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Flajolet, M; Greengard, P; Meijer, L | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Alam, MS; Hamid, H; Khan, I; Tantray, MA | 1 |
| Duan, Y; Han, J; Hou, S; Liao, C; Wang, Q; Xie, Z; Yang, X | 1 |
| Khuri, FR; Li, S; Oh, YT; Sun, SY; Yue, P | 1 |
| Aono, Y; Ichikawa, M; Iizumi, Y; Sakai, T; Sowa, Y | 1 |
3 review(s) available for sb 216763 and Neoplasms
| Article | Year |
|---|---|
Pharmacological inhibitors of glycogen synthase kinase 3.
Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Neoplasms; Nervous System Diseases; Parasitic Diseases; Signal Transduction; Stem Cells; Structure-Activity Relationship | 2004 |
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Topics: Alzheimer Disease; Animals; Bipolar Disorder; Clinical Trials as Topic; Diabetes Mellitus; Drug Discovery; Glycogen Synthase Kinase 3; Humans; Models, Molecular; Neoplasms; Patents as Topic; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2017 |
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhibitors | 2022 |
3 other study(ies) available for sb 216763 and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Enzyme Inhibitors; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; HCT116 Cells; Humans; Indoles; Lipogenesis; Maleimides; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Neoplasms; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases; Transfection; Ubiquitin-Protein Ligases | 2016 |
Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells.
Topics: Annexin A5; Apoptosis; Bufanolides; Cardiotonic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cyclin D1; G1 Phase; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Medicine, Chinese Traditional; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Retinoblastoma Protein | 2015 |